Although the fenofibrate results provide compelling evidence that PPARα agonism by systemically administered small molecules is a clinically validated avenue for the treatment of retinal diseases, new PPARα agonists with improved pharmacokinetic and pharmacodynamic profiles are required. Here, PPARA is linked to Abnormal retinal morphology.